RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
for Systemic Sclerosis
10 locations incl. New Haven
Sponsor: Cabaletta Bio
Sex: All·Age: 18 - 75
Code: NCT06328777·Phase 1, Phase 2·Recruiting